The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Prognostic value of tumor deposits in stage III colon cancer patients
Romain Cohen, MD, PhD, Saint-Antoine Hospital, AP-HP, Paris, France, outlines a post-hoc analysis of the CALGB/SWOG 80702 study (NCT01150045), evaluating the prognostic value of tumor deposits in stage III colon cancer patients. The results of this analysis suggest that the number of tumor deposits has a linear deleterious effect on the prognosis of patients with colon cancer and may be a valuable tool in increasing the accuracy of TNM staging. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
